INTRODUCTION
Atherosclerosis involves a complex interplay between metabolic pathways governing lipid deposition, inflammatory and immune responses to oxidized lipids, and endothelial dysfunction. Myocardial infarction (MI) and stroke ensue when these processes culminate in thrombosis. Markers of inflammation, such as C-reactive protein (CRP), myeloperoxidase (MPO), and leukocyte levels are strong predictors of cardiovascular death, MI, and stroke. Similarly, individuals with chronic inflammatory conditions such as rheumatoid arthritis (RA) or systemic lupus erythematous (SLE) are at higher risk for the development and complications of atherosclerosis. This review will summarize recent observations that provide mechanistic insight into the molecular and cellular links between inflammation and thrombosis in the context of cardiovascular disease (CVD), which support the concept of a thromboinflammatory state.
PLATELET-MEDIATED INTERACTIONS
Platelet activation results in the expression of cell surface receptors, adhesion, and small molecules that can alter the properties of leukocytes, endothelial cells, and other vascular cells [1] . Thus, both by direct contact and through the release of bioactive mediators, platelets may influence the function of surrounding cells. Activated platelets produce eicosanoids and platelet activating factor, which have potent effects on inflammation and immunity. Recent work has focused on biologically active cargo released from intracellular platelet granules upon activation. Platelet dense granules store the purine nucleotides adenosine diphosphate (ADP) and adenosine triphosphate (ATP), which have roles in thrombosis, inflammation, ischemia-reperfusion injury, and potentially acute lung injury [2 & ]. Platelet release of serotonin from dense granules may modulate mitogenic and inflammatory responses and has been implicated in neutrophil rolling and adhesion to inflamed endothelium [3 of dense granules that are released during platelet activation; these influence coagulation and inflammation differentially based on the size of the polyphosphate polymer [4, 5] .
Platelet a-granules contain adhesive proteins, coagulation, mitogenic and angiogenic factors, CXC and CC chemokines, and other factors. One of the most abundant a-granule proteins, platelet factor 4 (PF4/CXCL4) may influence both neutrophils and macrophages and has been implicated in atherosclerosis and vascular smooth muscle cell (VSMC) responses after injury. PF4 acts at least in part through Kruppel-like factor 4 to transcriptionally regulate VSMCs, reduce their differentiation and promote an inflammatory phenotype [6] .
After translocation from a-granules to the cell surface, P-selectin binds to leukocyte P-selecting glycoprotein ligand 1 to initiate physical interactions between the cells. Platelet-leukocyte interactions are then stabilized by b2-integrin-dependent events to promote efficient leukocyte recruitment at the site of vascular injury and the formation of mixed plateletleukocyte conjugates in circulating blood ( Fig. 1 [7] ). Platelet-leukocyte aggregates form and may predict outcomes in acute coronary syndromes (ACSs) and following percutaneous coronary intervention (PCI) [8, 9] . In the setting of ACS and PCI, platelet-leukocyte aggregates correlate with the inflammatory marker CRP and with biomarkers of myocardial necrosis, such as troponin [10, 11] . Antiplatelet therapy, in particular with P2Y12 antagonists, has been associated with reductions in platelet-leukocyte aggregate formation. In several clinical studies, use of the P2Y12 antagonist clopidogrel was linked to reductions in P-selectin expression, whereas aspirin was not. The active metabolites of both clopidogrel and prasugrel reduce platelet-leukocyte aggregate formation in vitro and in animal models [12,13 & ]. Antiplatelet therapy has been variably associated with reductions in biomarkers of systemic inflammation, including decreased CRP, CD40L, and P-selectin in a variety of disease states, including: CVD, cerebrovascular disease, diabetes, and renal transplantation [14] [15] [16] [17] . Reduced expression of interleukin-1a (IL-1a), 2, 6, 13, 10, tumor necrosis factor (TNF)a, TNFb, and CRP has been observed in patients after long-term treatment with clopidogrel [18] . How much of the clinical benefit of antiplatelet therapy derives from reductions in platelet-mediated inflammation is not known.
Strategies to target directly interactions between platelets, endothelial cells, and leukocytes are the focus of ongoing studies. On the basis of strong data from preclinical animal models, P-selectin appears to be an attractive target to block thromboinflammatory cell interactions. The recombinant monoclonal antibody to P-selectin, inclacumab, was tested in the Effect of P-selectin Antagonist Inclacumab in Acute Coronary Syndromes (SELECT-ACS) trial in which patients (n ¼ 544) presenting with ACS were randomized to receive placebo, or one of two doses of inclacumab (5 or 20 mg/kg) administered as a single infusion [19 && ]. In patients who underwent PCI (n ¼ 322), those receiving the higher dose of inclacumab had a reduction in cardiac injury as assessed by plasma levels of troponin I and creatinine kinase MB (CK-MB) levels, although both endpoints barely missed statistical significance (P ¼ 0.05). There was also a corresponding decrease in soluble P-selectin levels. The study was underpowered to detect clinical events; however, there were numerically more deaths, MIs, and strokes in the two groups that received inclacumab than in the placebo control. Nonetheless, the effects on cardiac biomarkers, and especially the reduction in CK-MB more than three times the upper limit of normal, may portend a clinical value to P-selectin inhibition.
NEUTROPHIL-MEDIATED INTERACTIONS
Leukocytosis, and in particular elevations in neutrophil count, is a robust predictor of increased morbidity and mortality of ischemic vascular disease. Leukocytosis has emerged as a risk factor for both short-term and long-term complications in studies of more than 350 000 patients. Ischemic events themselves elicit an inflammatory response and elevations in white blood count may reflect the extent of injury. However, in the CAPRIE trial of patients with recent MI, stroke, or peripheral vascular disease, leukocyte counts obtained within 1 week prior to a recurrent ischemic event were
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Ongoing clinical trials are evaluating the benefit of anti-inflammatory therapy in CVD and strategies aimed at lowering leukocyte count may prove to be a viable method of targeting inflammation and thrombosis. significantly higher than those observed at baseline or in days 8-120 before an event. Additionally, the degree of accumulation of neutrophils in aspirated thrombus of patients presenting with ST-segment elevation myocardial infarction is an independent predictor of a poor myocardial blush grade, ST-segment resolution, and left ventricular function at 6 months [20] . These findings suggest that leukocytosis may causally impact the development of ischemic events.
Several regulators of neutrophilia and monocytosis have been proposed to impact the development of CVD. Hematopoietic stem cell proliferation and mobilization result in more monocytes and neutrophils originating from the bone marrow. Additionally, stem cell mobilization to spleen can ].
There are numerous ways in which leukocytes impact CVD. On their own, and synergistically with platelets, these generate tissue factor (TF), microparticles, and surfaces for thrombin generation to enhance fibrin formation. Leukocyte homotypic and platelet-leukocyte heterotypic aggregates may cause rheological compromise of microvasculature. Neutrophils and monocytes also promote CVD through the generation of inflammatory mediators, tissue infiltration, and oxidation of lipoproteins and other proteins. Neutrophil release of the serine proteases elastase and cathepsin G promote efficient thrombus formation in mice by stabilizing fibrin deposition, likely by proteolytic inactivation of endogenous anticoagulants [26] .
In the last several years, evidence has emerged for a key role for neutrophil release of extracellular traps (NETs) in thrombotic conditions. In response to strong stimulation, neutrophils extrude NETs that consist of DNA and histones in a process that involves histone citrullinated by peptidylarginine deiminase 4 (PAD 4), chromatin unwinding, breakdown of nuclear membranes and cytolysis [27 & ]. A key function of the extracellular chromatin material is to entrap and confine microbes to promote their destruction. The chromatin fibers may also serve as a scaffold for clot formation, promote extrinsic and intrinsic activation of the coagulation cascade, and provide resistance to thrombolysis. 
ANTI-INFLAMMATORY THERAPY IN CARDIOVASCULAR DISEASE
A number of anti-inflammatory therapies have been tested in patients with acute MI (AMI), however, as of yet no therapy has emerged as having a demonstrable benefit in this setting. An example is the development of the complement (C5) inhibitor pexelizumab, which reduces neutrophil count and showed promise in several preclinical studies and a phase 2 trial of individuals with AMI undergoing PCI [36] , although this was not the case in a trial of AMI patients receiving thrombolysis [37] . Also, in the Assessment of Pexelizumab in Acute Myocardial Infarction trial, a phase 3 study of 6000 patients, pexelizumab had no effect on 90-day mortality [38] . The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial demonstrated that statin therapy prevented cardiovascular events in individuals with a high inflammatory burden (assessed by CRP levels >2 mg/l), normal low density lipoprotein (LDL)-cholesterol values (LDL < 130 mg/dl), and no known CVD. In this patient population, rosuvastatin at a dose of 20 mg daily reduced by 54% the risk of first-ever MI, stroke by 43% [39] , and deep vein thrombosis or pulmonary embolism by 43% [40] . Due to the effects of statins on cholesterol metabolism, the JUPITER trial could not definitively establish an anti-inflammatory benefit. However, the lowest clinical event rates were observed in individuals who achieved LDL-cholesterol levels less than 70 mg/dl and hsCRP levels less than 2 mg/l. The effect of anti-inflammatory therapy on vascular events is currently being tested in the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) and the Cardiovascular Inflammation Reduction Trial (CIRT). In CANTOS, individuals with stable coronary artery disease and elevated hsCRP will be randomized to receive the IL-1b inhibitor canakinumab or placebo [41] . CIRT examines the effect of low-dose methotrexate in individuals with type 2 diabetes or metabolic syndrome who have had a heart attack [42] . Both trials will measure rates of recurrent MI, stroke, and cardiovascular death. In patients with RA, evidence suggests that methotrexate treatment [43] and TNFa inhibitors [44] may improve cardiovascular outcomes. Etanercept, a recombinant fusion protein containing the human TNF receptor that scavenges TNFa, has been investigated in congestive heart failure [45] and administered to a small number of patients with AMI [46 & ], although with disappointing results.
ANTI-THROMBOTIC STRATEGIES IN INFLAMMATION AND SEPSIS
On the basis of compelling experimental evidence that thrombosis contributes to inflammatory states, several antithrombotic strategies have been explored in systemic inflammatory responses and sepsis. After initial promising results in sepsis based on the results of the Protein C Evaluation in World Wide Severe Sepsis (PROWESS) trial [47] , activated protein C (drotrecogin a) received US Food and Drug Administration approval that was subsequently limited to patients at high risk of death. In the large, international PROWESS-Shock study of critically ill adults with septic shock, drotrecogin a did not reduce mortality at either 28 or 90 days, as compared with placebo [48 & ], and has subsequently been removed from the market. High-dose antithrombin has not demonstrated benefit and is associated with increased bleeding in severe sepsis [49] , although it may have efficacy in disseminated intravascular coagulation associated with sepsis [50 & ]. Likewise, recombinant tissue factor pathway inhibitor (rTFPI; tifacogin) failed to improve outcomes in sepsis [51] . Recombinant thrombomodulin has shown promising results in phase 2 sepsis studies, especially among individuals with coagulopathy and respiratory or cardiac dysfunction, and a phase 3 trial is currently underway [52 & ]. Thrombocytopenia in the setting of sepsis portends poor outcomes for reasons that are not known. Platelets express TLRs, including TLR2 and TLR4 that recognize the bacterial peptidoglycan and lipopolysaccharide (LPS), respectively [53] [54] [55] . Interactions between LPS and platelet TLR4 have been implicated in sepsis-induced thrombocytopenia, pulmonary fibrin deposition, and microvascular thrombosis in animal models [54] . Platelet activation and sequestration in pulmonary tissue is a key feature in inflammatory states and may contribute to acute lung injury and acute respiratory distress syndrome (ARDS) [56 & ]. Antiplatelet therapy with clopidogrel or prasugel reduces LPS-mediated thrombocytopenia, fibrin deposition in the lungs, and inflammatory mediator upregulation in mice [13 & ,54,57], whereas ticagrelor therapy prevents lung damage and neutrophil infiltration in the cecal ligation puncture model of sepsis in mice (content.onlinejacc.org/data/Journals/JAC/926556/ 00716.pdf).
Retrospective and observational clinical studies hint that antiplatelet therapy may improve outcomes in critical illness, especially in individuals at risk for acute lung injury. In a single center experience of 224 patients hospitalized with pneumonia requiring intensive care, those who were taking antiplatelet therapy (aspirin, clopidogrel, or ticlopidine) had shorter lengths of stay [57] . A subsequent larger study (n ¼ 615) by the same investigators documented a reduction in mortality in medical and surgical intensive care patients who were receiving aspirin or clopidgorel [58] . In population-based observational studies, prehospital antiplatelet therapy was associated with reductions in indices of acute lung injury and ARDS [59,60 &, 61] , although, a more recent publication by one of the groups failed to confirm the benefit of aspirin [62] . The ongoing Lung Injury Prevention With Aspirin trial will test the hypothesis that early aspirin (325 mg followed by 81 mg daily) given within 12 h of hospitalization to individuals at risk for acute lung injury will improve outcomes [63] . This work demonstrated that neutrophilia and monocytosis in diabetic mice is the result of neutrophil production of S100A8/S100A9 that acts on the receptor for advanced glycation end products on common myeloid progenitor cells to enhance myelopoiesis, and thereby promote atherosclerosis. NET formation was observed in a murine model of lupus and an inhibitor of PADs, which prevents citrullination of histones, and therefore NET formation, reduced lupus-like disease activity, improved endothelial function, and attenuated the prothrombotic phenotype. 35.
